Articles Tagged With:
-
Pregnancy in Abortion-Ban States Is Becoming More Dangerous
Maternal care and delivery services already are lacking for many pregnant people in the United States, especially in states that have enacted the most restrictive abortion bans nationally. The COVID-19 pandemic and subsequent healthcare labor shortages resulted in more hospitals ending maternal care and delivery. The overturn of Roe v. Wade likely will worsen this already worrisome situation as fewer ED physicians will be trained and experienced in performing an abortion procedure — even to save a pregnant patient’s life.
-
Potentially Wide-Ranging Effects of Abortion Bans on Women’s Health and Safety
In June 2022, the Supreme Court’s decision in Dobbs v. Jackson Women’s Health Organization overturned the constitutional right to abortion care. Data are not yet available on whether medical schools and residency programs in abortion-ban states will teach students about abortion or provide any opportunities for hands-on experience with abortion care. Or they could be taught abortion procedures without actual human patients. Media reports indicate that medical students are using papayas in place of a cervix to learn the procedure in some cities.
-
Premenstrual Anxiety, Mood Swings Are Common Among Women Worldwide
New research shows that women worldwide experience unpleasant premenstrual symtoms, including food cravings (85%) and mood swings or anxiety (64%). Other reported symptoms included fatigue, irritability, bloating, and breast tenderness.
-
Telehealth for Contraception Works, Increasing Access for Patients
Contraceptive care providers and staff wish to sustain telehealth long past the COVID-19 pandemic era in which telehealth was more widely used, according to a recent study of telehealth in Illinois.
-
FDA’s Change to Emergency Contraception Labeling Is Good News for Women
In a move that expands access to contraception, the FDA announced that it was changing packaging labels for Plan B, the emergency contraceptive pill that is available over the counter. The box no longer will carry the baseless claim that the pill may prevent a fertilized egg from implanting in the womb.
-
Social Media Trends Are Moving Against Contraception Access
Reproductive health advocates and providers should be aware of a disturbing social media trend that appears to be moving in the same direction as the early anti-Roe efforts in the 1980s. Decades of attacks on abortion changed enough people’s opinions on abortion to lay the groundwork for the Supreme Court’s Dobbs v. Jackson Women’s Health Organization decision.
-
Fully Funded Access to Contraception Can Change an Entire Population’s Lives
The results of Colorado’s contraception expansion experiment are in, showing a dramatic improvement in women’s lives during the period in which Title X programs were fully funded through a grant. The Colorado Family Planning Initiative profoundly affected adolescent girls and young adults, resulting in a 6% to 12% increase in women obtaining their college degrees compared to earlier cohorts that did not benefit from the expanded contraception program, according to study results.
-
Probiotics and Iron Intake in Pregnancy
In a randomized controlled trial, a significantly smaller decrease in serum ferritin was observed in pregnant women with the intake of a Lactiplantibacillus plantarum 299v supplement containing a low dose of iron, folic acid, and ascorbic acid than in the placebo group.
-
Provider Perceptions of Neonatal Survival for Fetuses Born at 22 Weeks of Gestation
Prognostic differences exist among neonatal and obstetric care providers when neonates are delivered at 22 weeks of gestation. However, there are no statistically significant differences in the gestational age at which providers recommend active treatment or antenatal corticosteroids.
-
New Treatments for Uterine Fibroids
In this prospective, open-label, single-arm trial of 149 individuals with heavy menstrual bleeding and uterine leiomyomas, daily relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) resulted in a mean menstrual blood loss reduction of 90%, and 70% of the participants achieved amenorrhea by the end of the 52-week period. Similar results were found for other arms of the trial among women who crossed over from placebo and relugolix-only therapy to relugolix combination therapy.